Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpRegen in Advanced Dry-Form Age-Related Macular Degeneration
NCT02286089Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2015
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of OpRegen in age-related macular degeneration (AMD), sponsored by Roche. Primary endpoints: Treatment Emergent Adverse Events at 6.5 years and Intraocular Pressure at 12 months. Started Apr 2015; status: active, not recruiting.
02
Drugs
OpRegen
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02286089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286089.